Our Mission
Electra is a late clinical-stage biopharmaceutical company pioneering a new class of precision medicines that target signal regulatory proteins (SIRP) to selectively deplete disease-driving cells while preserving normal immune function — advancing treatments for immune-mediated diseases and cancer.